Celtic Pharma

Cantab Biopharmaceuticals Limited is a biopharmaceutical company based in Cambridge, United Kingdom, specializing in the discovery and development of biosuperior protein therapeutics. Founded in 2006, the company operates within the vibrant Cambridge Science Park, a prominent hub for biotechnology in Europe. Cantab focuses on enhancing previously marketed, off-patent biologics by employing advanced technologies in protein expression and engineering, process development, and manufacturing. The company's work aims to improve critical drug characteristics such as product presentation, stability, pharmacokinetics, pharmacodynamics, immunogenicity, and drug delivery. Through its extensive experience in biopharmaceutical discovery and good manufacturing practices (GMP), Cantab seeks to expedite the development of innovative therapies targeting hematology and infectious diseases.

Novacta Biosystems Ltd, founded in 2003, specializes in the development of biopharmaceuticals aimed at treating bacterial infections, particularly those caused by drug-resistant strains. The company employs a dual business model that combines biocatalysis and microbial pathway engineering services with the discovery and development of novel small peptide molecules known as lantibiotics. These innovative therapies target various bacterial infections, including Clostridium difficile. By leveraging the expertise of GSK's Biotransformation and Natural Products scientific team, Novacta has established a robust infectious disease therapeutic pipeline, focusing on delivering effective anti-infective solutions.

Xenova publicly quoted biotechnology company focused on the development of novel drugs to treat cancer and addiction.